MAPK3 and melanoma: Interestingly, it has been demonstrated that targeting V600EBRAF and MEK1/2 with inhibitors leading to ERK1/2 inhibition causes a relief of ERK-dependent feedback and reactivation of ligand-dependent signal transduction in melanoma and stroma [1–3,5].